Overview

A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease

Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to evaluate the efficacy and safety of treatment with 4000 litre (L) alglucosidase alfa (Lumizyme®) in Pompe participants.
Phase:
Phase 4
Details
Lead Sponsor:
Genzyme, a Sanofi Company